Table 3.
Association analysis of 5 genotyped SNPs of the MMP9, ALOX5AP, MTHFR, FGB, and eNOS genes with CES.
| Gene | SNP | Genotype | AF patients with CES (n = 479) | AF patients without CES (n = 580) | P | P HWE | ||
|---|---|---|---|---|---|---|---|---|
| No | Frequency | No | Frequency | |||||
| MMP9 | C1562T | CC | 293 | 61.5% | 357 | 61.8% | 0.963 | 0.921 |
| CT | 160 | 33.5% | 194 | 33.5% | ||||
| TT | 24 | 5.0% | 27 | 4.7% | ||||
| C:T | 0.78:0.22 | 0.79:0.21 | 0.846 | |||||
| ALOX5AP | SG13S114A/T | AA | 147 | 30.7.2% | 205 | 35.3% | 0.116 | 0.500 |
| AT | 256 | 53.4% | 273 | 47.1% | ||||
| TT | 76 | 15.9% | 102 | 17.6% | ||||
| A:T | 0.57:0.43 | 0.59:0.41 | 0.495 | |||||
| MTHFR | 677 C/T | CC | 285 | 59.5% | 321 | 55.5% | 0.425 | 0.298 |
| CT | 162 | 33.8% | 213 | 36.9% | ||||
| TT | 32 | 6.7% | 44 | 7.6% | ||||
| C:T | 0.76:0.24 | 0.74:0.26 | 0.195 | |||||
| FGB | 455 G/A | GG | 271 | 56.6% | 382 | 65.9% | 0.001 | 0.929 |
| GA | 172 | 35.9% | 177 | 30.5% | ||||
| AA | 36 | 7.5% | 21 | 3.6% | ||||
| G:A | 0.75:0.25 | 0.81:0.19 | < 0.001 | |||||
| eNOS | G894T | GG | 338 | 70.6% | 418 | 72.3% | 0.437 | 0.058 |
| GT | 129 | 26.9% | 140 | 24.2% | ||||
| TT | 12 | 2.5% | 20 | 3.5% | ||||
| G:T | 0.84:0.16 | 0.84:0.16 | 0.802 | |||||
AF: atrial fibrillation; CES: cardioembolic stroke; SNP: single nucleotide polymorphism; MMP-9: matrix metallopeptidas-9 gene; ALOX5AP: arachidonate 5-lipoxygenase-activating protein gene; MTHFR: methylene tetrahydrofolate reductase gene; FGB: the β-fibrinogen gene; and eNOS: endothelial nitric oxide synthase gene.